Sanofi and Regeneron Report Positive Results with Sarilumab


and with in First Phase 3 Rheumatoid Arthritis Registration Trial
Sarilumab, Given Subcutaneously Every Other Week, Met All Three Co-Primary Endpoints
Sarilumab is the First Fully-Human Monoclonal Antibody Directed Against the Interleukin-6 Receptor (IL-6R)

PARIS and TARRYTOWN, N.Y., Nov. 22, 2013 /PRNewswire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the SARIL-RA-MOBILITY Phase 3 clinical trial in adult patients with active rheumatoid arthritis (RA) who were inadequate responders to methotrexate (MTX) therapy, sarilumab (the first fully-human anti-IL-6R monoclonal antibody) treatment in combination with MTX improved disease signs and symptoms as well as physical function, and inhibited progression of joint damage.

“IL-6 blockade is emerging as an important therapeutic approach for rheumatoid arthritis,” said Neil Graham, M.B.B.S., M.D., M.P.H., Vice President, Program Direction, Immunology and Inflammation, Regeneron Pharmaceuticals.  “We are encouraged with these Phase 3 results, which demonstrated efficacy at both doses of sarilumab, each administered every other week.”

The 52 week SARIL-RA-MOBILITY Phase 3 trial enrolled approximately 1,200 patients with active, moderate-to-severe rheumatoid arthritis, and who were inadequate responders to MTX therapy. Patients were randomized to one of three subcutaneous treatment groups, all in combination with MTX and dosed every other week: sarilumab 200 milligrams (mg), sarilumab 150 mg, or placebo.

Both sarilumab groups showed clinically relevant and statistically significant improvements compared to the placebo group in all three co-primary endpoints (p<0.0001).

    (1) Improvement in signs and symptoms of RA at 24 weeks, as measured by the American College of Rheumatology score of 20 percent improvement (ACR20).

        66 percent…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS